XWARPUR
Market cap15mUSD
Dec 23, Last price
16.64PLN
1D
7.22%
1Q
-16.80%
IPO
1.46%
Name
Pure Biologics SA
Chart & Performance
P/E
—
P/S
656.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.91%
Rev. gr., 5y
-60.22%
Revenues
95k
-85.65%
Net income
-36m
L+35.35%
CFO
-23m
L+33.79%
Profile
Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 95 -85.65% | 662 160.63% | 254 -55.59% | |||||
Cost of revenue | 9,208 | 37,884 | 28,658 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (9,113) | (37,222) | (28,404) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 769 | 1,306 | ||||||
Tax Rate | ||||||||
NOPAT | (9,113) | (37,991) | (29,710) | |||||
Net income | (35,694) 35.35% | (26,372) 101.76% | (13,071) 7.98% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 18,861 | 52,110 | ||||||
BB yield | -45.38% | -30.16% | ||||||
| Debt | ||||||||
Debt current | 86 | 1,096 | 1,113 | |||||
Long-term debt | 13,069 | 4,626 | 5,113 | |||||
Deferred revenue | 74 | 112 | ||||||
Other long-term liabilities | 39 | 1,000 | ||||||
Net debt | 9,549 | 3,443 | 33 | |||||
| Cash flow | ||||||||
Cash from operating activities | (23,262) | (17,387) | (24,035) | |||||
CAPEX | (176) | (5,758) | (673) | |||||
Cash from investing activities | 391 | 15,345 | (28,478) | |||||
Cash from financing activities | 24,218 | (1,876) | 49,735 | |||||
FCF | (6,457) | (42,569) | (37,515) | |||||
| Balance | ||||||||
Cash | 3,606 | 7,178 | 32,929 | |||||
Long term investments | (4,899) | (26,736) | ||||||
Excess cash | 3,601 | 2,246 | 6,180 | |||||
Stockholders' equity | (92,596) | 18,297 | 39,486 | |||||
Invested Capital | 107,427 | 18,951 | 36,529 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 3,288 | 2,221 | 2,221 | |||||
Price | 12.64 -45.04% | 23.00 -70.44% | 77.80 -30.22% | |||||
Market cap | 41,564 -18.64% | 51,086 -70.44% | 172,803 -6.30% | |||||
EV | 51,113 | 54,529 | 172,836 | |||||
EBITDA | (3,329) | (34,725) | (25,484) | |||||
EV/EBITDA | ||||||||
Interest | 3,833 | 329 | 227 | |||||
Interest/NOPBT | ||||||||